Regulatory Open Forum

 View Only
  • 1.  One DSUR for All IND's with Same Investigational Drug

    This message was posted by a user wishing to remain anonymous
    Posted 21-Sep-2019 08:15
      |   view attached
    This message was posted by a user wishing to remain anonymous

    Hello RAPS Community,

    I understand that the Guidance for Industry: E2F Development Safety Update Report Section 2.1 states that sponsors should submit a single DSUR for an an active substance, the "Development International Birth Date* (DIBD) is used to determine the start of the annual period for the DSUR," and the "data lock point of the DSUR should be the last day of the one-year reporting period."

    Questions:
    1.) If one submits a single DSUR for an active substance and there are multiple IND's that utilize the same active substance, how does one determine the "DIBD" and "data lock point" for the multiple IND's? Is it determined based on the primary IND?

    2.) For the other IND's that cross-reference the primary IND, must one notify the FDA to refer to the DSUR submitted for the primary IND?

    3.) As a part of the DSUR process, must one also update the IB annually to reflect the updated safety data or is it optional?

    I hope the questions make sense - any guidance is appreciated. Thank you!

    Attachment(s)



  • 2.  RE: One DSUR for All IND's with Same Investigational Drug

    Posted 22-Sep-2019 08:30
    1) The DIBD is the date that the active substance was first cleared for clinical investigation by a regulatory authority. So, if first cleared by FDA then it would be the "primary" IND.
    2) Since the DSUR will cover all INDs, which I assume are for different dosage forms and/or indications, the DSUR should be submitted to all INDs that include the active substance.
    3) The timing of updating the IB is dependent on the timing of clinical studies and when the new safety data needs to be reflected in it. Typically, it works to update annually at the time of the DSUR, but if the IB has already been updated and there is no new safety data to include the IB does not have to be updated again just for the DSUR. Since the updated IB will probably have been already submitted to FDA it does not have to be submitted again with the DSUR.

    ------------------------------
    Glen Park PharmD
    Executive Director, Regulatory Affairs and Quality Assurance
    Jersey City NJ
    United States
    ------------------------------



  • 3.  RE: One DSUR for All IND's with Same Investigational Drug

    Posted 23-Sep-2019 07:58
    Hello, 

    Questions:
    1.) If one submits a single DSUR for an active substance and there are multiple IND's that utilize the same active substance, how does one determine the "DIBD" and "data lock point" for the multiple IND's? Is it determined based on the primary IND?

    data based on primary IND, but you should indicate different compound details in DSUR.

    2.) For the other IND's that cross-reference the primary IND, must one notify the FDA to refer to the DSUR submitted for the primary IND?

    You may cross-reference DSUR from primary IND with simple indicating other IND #'s in FDA Form 1571 Box 9.

    3.) As a part of the DSUR process, must one also update the IB annually to reflect the updated safety data or is it optional?

    Yes, generally IB and DSUR goes to Agency around the same timing

    Thanks,


    ------------------------------
    Prakash Patel
    Sr. Manager Global Regulatory Affairs
    Cambridge MA
    United States
    ------------------------------



  • 4.  RE: One DSUR for All IND's with Same Investigational Drug

    This message was posted by a user wishing to remain anonymous
    Posted 24-Sep-2019 10:43
    This message was posted by a user wishing to remain anonymous

    So can one submit a combined DSUR if the two IND's that contain the same API are NOT cross referenced?  In our case, one is for an IR and the other an XR formulation.


  • 5.  RE: One DSUR for All IND's with Same Investigational Drug

    Posted 24-Sep-2019 11:09
    Two comments:

    1. I recommend referring to the DSUR E2F guidance from 2011 as it will correctly answer some of the questions asked here.
    2. It is efficient to have all INDs that contain the same API  listed in Item 9 of the 1571 as it facilitates cross-referencing a lot of submissions that are relevant for the API, but not necessarily to the DP. 

    https://www.fda.gov/media/71255/download

    ------------------------------
    Glen Park PharmD
    Executive Director, Regulatory Affairs and Quality Assurance
    Jersey City NJ
    United States
    ------------------------------